Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A2 | O95436 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 11/20 | 0.45 |
| ▸ | BRAF | P15056 | 9/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | GLS | O94925 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL46660 | 0.89 | SLC34A2 (0.62) | SLC34A2MAPK1RAF1BRAFROCK2 | |
| SCHEMBL39854 | 0.88 | SLC34A2 (0.56) | SLC34A2MAPK1RAF1BRAFROCK2 | |
| SCHEMBL39901 | 0.87 | MAPK1 (0.56) | SLC34A2MAPK1RAF1BRAFROCK2 | |
| SCHEMBL40151 | 0.85 | MAPK1 (0.49) | SLC34A2MAPK1RAF1BRAFROCK2 | |
| SCHEMBL6000572 | 0.84 | SLC34A2 (0.55) | SLC34A2MAPK1ROCK2ROCK1MAPK14 | |
| SCHEMBL15432553 | 0.83 | SLC34A2 (0.47) | SLC34A2MAPK1RAF1BRAFMAPK14 | |
| SCHEMBL46970 | 0.83 | SLC34A2 (0.46) | SLC34A2MAPK1RAF1BRAFROCK2 | |
| SCHEMBL18482946 | 0.82 | SLC34A2 (0.59) | SLC34A2ROCK2ROCK1 | |
| SCHEMBL39907 | 0.80 | MAPK1 (0.49) | SLC34A2MAPK1ROCK2ROCK1MAPK14 | |
| SCHEMBL45514 | 0.79 | ALDH1A1 (0.45) | SLC34A2MAPK1ROCK2ROCK1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A2, SLC34A1, SLC10A2 | SLC34A2 1/4885MAPK1 2611/4885RAF1 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.